{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-117691","form_type":"8-K","ticker":"GPCR","cik":"0001888886","company_name":"Structure Therapeutics Inc.","filed_at":"2024-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.260075+00:00","generated_at":"2026-05-30T01:09:30.752991+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Structure Therapeutics reports Q3 2024 net loss of $34M; first patients dosed in Phase 2b ACCESS obesity study","bullets":["Cash, cash equivalents and short-term investments $915.3M; expected to fund operations through at least 2027 excluding Phase 3 registrational studies.","Net loss $34.0M for Q3 2024 vs $23.9M in Q3 2023; R&D expenses $32.6M (up from $17.5M) driven by GLP-1R program advancement.","First patients dosed in Phase 2b ACCESS study of GSBR-1290 for obesity; topline data expected Q4 2025.","Oral amylin receptor agonist development candidate expected by end of 2024; GIPR candidate expected H1 2025.","ANPA-0073 (APJR agonist) Phase 2 ready; long-term toxicology studies ongoing, expected completion in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-117691","json":"https://secwatch.observer/filing/0001104659-24-117691.json","markdown":"https://secwatch.observer/filing/0001104659-24-117691.md","text":"https://secwatch.observer/filing/0001104659-24-117691.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1888886/000110465924117691/0001104659-24-117691-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1888886/000110465924117691/tm2428324d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:09:30.752991+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}